Literature DB >> 21568678

Ubiquitin-specific proteases as cancer drug targets.

Wolfgang Sippl1, Vincent Collura, Frédéric Colland.   

Abstract

Ubiquitin-specific proteases are deubiquitinating enzymes involved in the removal of ubiquitin from specific protein substrates resulting in protein salvage from proteasome degradation, regulation of protein localization or activation. DNA alteration and overexpression in different cancer types, as well as involvement in many cancer-associated pathways, make ubiquitin-specific proteases attractive for the cancer drug discovery purposes. Their proteolytic function associated to available structural biology data reinforce their potential for pharmacological interference. Here, we review this class of enzymes as cancer drug targets in terms of validation and druggability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21568678     DOI: 10.2217/fon.11.39

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  20 in total

Review 1.  Mechanisms for regulating deubiquitinating enzymes.

Authors:  Cynthia Wolberger
Journal:  Protein Sci       Date:  2014-02-12       Impact factor: 6.725

2.  Saturation scanning of ubiquitin variants reveals a common hot spot for binding to USP2 and USP21.

Authors:  Isabel Leung; Ayelet Dekel; Julia M Shifman; Sachdev S Sidhu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-19       Impact factor: 11.205

3.  JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis.

Authors:  Takahiro Seki; Lijie Gong; Aislinn J Williams; Norio Sakai; Sokol V Todi; Henry L Paulson
Journal:  J Biol Chem       Date:  2013-04-26       Impact factor: 5.157

4.  USP14 inhibitor attenuates cerebral ischemia/reperfusion-induced neuronal injury in mice.

Authors:  Jia-Wei Min; Lanhai Lü; Jessica L Freeling; Doug S Martin; Hongmin Wang
Journal:  J Neurochem       Date:  2017-01-26       Impact factor: 5.372

5.  USP33 regulates centrosome biogenesis via deubiquitination of the centriolar protein CP110.

Authors:  Ji Li; Vincenzo D'Angiolella; E Scott Seeley; Sehyun Kim; Tetsuo Kobayashi; Wenxiang Fu; Eric I Campos; Michele Pagano; Brian David Dynlacht
Journal:  Nature       Date:  2013-03-14       Impact factor: 49.962

Review 6.  Role of Deubiquitinating Enzymes in DNA Repair.

Authors:  Younghoon Kee; Tony T Huang
Journal:  Mol Cell Biol       Date:  2015-12-07       Impact factor: 4.272

Review 7.  Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.

Authors:  Mariola J Edelmann; Benjamin Nicholson; Benedikt M Kessler
Journal:  Expert Rev Mol Med       Date:  2011-11-17       Impact factor: 5.600

8.  PPPDE1 promotes hepatocellular carcinoma development by negatively regulate p53 and apoptosis.

Authors:  Xingwang Xie; Xueyan Wang; Weijia Liao; Ran Fei; Nan Wu; Xu Cong; Qian Chen; Lai Wei; Yu Wang; Hongsong Chen
Journal:  Apoptosis       Date:  2019-02       Impact factor: 5.561

9.  The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis.

Authors:  Cheryl McFarlane; Suzanne McFarlane; Ian Paul; Kenneth Arthur; Michael Scheaff; Keith Kerr; Michael Stevenson; Dean A Fennell; James A Johnston
Journal:  Oncotarget       Date:  2013-10

10.  Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.

Authors:  Harish Potu; Luke F Peterson; Anupama Pal; Monique Verhaegen; Juxiang Cao; Moshe Talpaz; Nicholas J Donato
Journal:  Oncotarget       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.